Akari Therapeutics (AKTX) Non-Current Deferred Tax Liability (2024 - 2026)

Akari Therapeutics (AKTX) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 24.2% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 24.2% YoY) and the FY2025 annual result came in at $7.0 million, down 13.53% from the prior year.
• Non-Current Deferred Tax Liability fell to $6.1 million in Q1 2026 per AKTX's latest filing, from $7.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for AKTX reached as high as $8.0 million in Q4 2024 and fell as low as $6.1 million in Q1 2026.
• A 3-year average of $7.4 million and a median of $7.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability slipped 13.53% — and 2026, when it decreased 24.2%.
• Year by year, Non-Current Deferred Tax Liability stood at $8.0 million in 2024, then fell by 13.53% to $7.0 million in 2025, then declined by 12.34% to $6.1 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $6.1 million, $7.0 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.